Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Overview

Journal Front Oncol

Specialty Oncology

Date 2014 Mar 12

PMID 24616882

Citations 53

Authors

Ciara C OSullivan

Dominic H Moon

Elise C Kohn

Jung-Min Lee

Affiliations

Soon will be listed here.

Abstract

Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown clinical activity in patients with germline BRCA1/2 mutation (gBRCAm)-associated breast and ovarian cancers. Accumulating evidence suggests that PARPi may have a wider application in the treatment of cancers defective in DNA damage repair pathways, such as prostate, lung, endometrial, and pancreatic cancers. Several PARPi are currently in phase I/II clinical investigation, as single-agents and/or combination therapy in these solid tumors. Understanding more about the molecular abnormalities involved in BRCA-like phenotype in solid tumors beyond breast and ovarian cancers, exploring novel therapeutic trial strategies and drug combinations, and defining potential predictive biomarkers are critical to expanding the scope of PARPi therapy. This will improve clinical outcome in advanced solid tumors. Here, we briefly review the preclinical data and clinical development of PARPi, and discuss its future development in solid tumors beyond gBRCAm-associated breast and ovarian cancers.

Citing Articles

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial.

Piffoux M, Leary A, Follana P, Abdeddaim C, Joly F, Bin S Nat Commun. 2025; 16(1):1821.

PMID: 39979249 PMC: 11842746. DOI: 10.1038/s41467-025-56914-7.

Next-generation sequencing uncovers crucial mutated genes and potential therapeutic targets in ovarian cancer patients.

Zhao T, Dong X, Zhao T, Han Z Am J Transl Res. 2024; 16(10):5990-6007.

PMID: 39544793 PMC: 11558429. DOI: 10.62347/XNGV7396.

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Orlikova-Boyer B, Lorant A, Gajulapalli S, Cerella C, Schnekenburger M, Lee J Biomark Res. 2024; 12(1):47.

PMID: 38704604 PMC: 11069214. DOI: 10.1186/s40364-024-00594-w.

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.

Wei Y, He L, Liu T, Guo T, Xie C, Jia J Front Pharmacol. 2024; 15:1372077.

PMID: 38584601 PMC: 10995238. DOI: 10.3389/fphar.2024.1372077.

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.

Mittra A, Coyne G, Zlott J, Kummar S, Meehan R, Rubinstein L Cancer Chemother Pharmacol. 2023; 93(3):177-189.

PMID: 38010394 PMC: 10902014. DOI: 10.1007/s00280-023-04600-0.

References

Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A . Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs. 2011; 30(4):1493-500. DOI: 10.1007/s10637-011-9682-9. View

Bernstein C, Bernstein H, Payne C, Garewal H . DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002; 511(2):145-78. DOI: 10.1016/s1383-5742(02)00009-1. View

Vorechovsky I, Luo L, Ortmann E, Steinmann D, Dork T . Missense mutations at ATM gene and cancer risk. Lancet. 1999; 353(9160):1276. DOI: 10.1016/s0140-6736(05)75199-0. View

BELL D, Varley J, Szydlo T, Kang D, Wahrer D, Shannon K . Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 2000; 286(5449):2528-31. DOI: 10.1126/science.286.5449.2528. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

Thomas H, Calabrese C, Batey M, Canan S, Hostomsky Z, Kyle S . Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 2007; 6(3):945-56. DOI: 10.1158/1535-7163.MCT-06-0552. View

DAmours D, Desnoyers S, DSilva I, Poirier G . Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342 ( Pt 2):249-68. PMC: 1220459. View

Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B . PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004; 58(2):410-9. DOI: 10.1016/j.ijrobp.2003.09.053. View

10.

Palma J, Wang Y, Rodriguez L, Montgomery D, Ellis P, Bukofzer G . ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009; 15(23):7277-90. DOI: 10.1158/1078-0432.CCR-09-1245. View

11.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

12.

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

13.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S . EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 2003; 115(5):523-35. DOI: 10.1016/s0092-8674(03)00930-9. View

14.

Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E . Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res. 2012; 11(2):140-8. DOI: 10.1158/1541-7786.MCR-12-0401. View

15.

Haince J, Kozlov S, Dawson V, Dawson T, Hendzel M, Lavin M . Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem. 2007; 282(22):16441-53. DOI: 10.1074/jbc.M608406200. View

16.

Marsit C, Liu M, Nelson H, Posner M, Suzuki M, Kelsey K . Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2003; 23(4):1000-4. DOI: 10.1038/sj.onc.1207256. View

17.

Bedikian A, Papadopoulos N, Kim K, Hwu W, Homsi J, Glass M . A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009; 27(7):756-63. DOI: 10.1080/07357900802709159. View

18.

Shelton J, Waxweiler T, Landry J, Gao H, Xu Y, Wang L . In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys. 2013; 86(3):469-76. DOI: 10.1016/j.ijrobp.2013.02.015. View

19.

Marks J, Golas B, Kirchoff T, Miller V, Riely G, Offit K . EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thorac Oncol. 2008; 3(7):805. DOI: 10.1097/JTO.0b013e31817e4664. View

20.

Khan O, Gore M, Lorigan P, Stone J, Greystoke A, Burke W . A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011; 104(5):750-5. PMC: 3048218. DOI: 10.1038/bjc.2011.8. View